BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,096 filers reported holding BAXTER INTL INC in Q4 2020. The put-call ratio across all filers is 0.87 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $313,000 | +22.3% | 4,035 | +26.5% | 0.01% | 0.0% |
Q4 2021 | $256,000 | -40.5% | 3,189 | -40.4% | 0.01% | -33.3% |
Q3 2021 | $430,000 | -13.8% | 5,350 | -13.7% | 0.01% | -10.0% |
Q2 2021 | $499,000 | -53.9% | 6,200 | -51.7% | 0.01% | -60.0% |
Q1 2021 | $1,082,000 | +322.7% | 12,824 | +302.1% | 0.02% | +316.7% |
Q4 2020 | $256,000 | +3.2% | 3,189 | +3.2% | 0.01% | -14.3% |
Q3 2020 | $248,000 | -6.8% | 3,089 | 0.0% | 0.01% | -12.5% |
Q2 2020 | $266,000 | +3.5% | 3,089 | -2.4% | 0.01% | -11.1% |
Q1 2020 | $257,000 | +15.8% | 3,164 | +18.8% | 0.01% | +50.0% |
Q4 2019 | $222,000 | -70.6% | 2,664 | -71.3% | 0.01% | -75.0% |
Q1 2019 | $754,000 | +164.6% | 9,268 | +151.0% | 0.02% | +84.6% |
Q3 2018 | $285,000 | +25.0% | 3,693 | +19.4% | 0.01% | +18.2% |
Q2 2018 | $228,000 | +13.4% | 3,093 | 0.0% | 0.01% | +10.0% |
Q1 2018 | $201,000 | -22.1% | 3,093 | -22.5% | 0.01% | -9.1% |
Q4 2017 | $258,000 | -6.5% | 3,993 | -9.4% | 0.01% | -21.4% |
Q3 2017 | $276,000 | -4.5% | 4,406 | -7.7% | 0.01% | -6.7% |
Q2 2017 | $289,000 | +39.6% | 4,771 | +19.5% | 0.02% | +36.4% |
Q1 2017 | $207,000 | – | 3,991 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |